Immunohistochemical Analysis of CD99 and PAX8 in a Series of 15 Molecularly Confirmed Cases of Ewing Sarcoma

Chinchilla-Tábora, Luís Miguel; Rodríguez-Parets, Javier Ortiz; Morais, Idalia Gonzalez; Sayagués, J M; Cruz, María Dolores Ludeña de la

doi:10.1155/2020/3180798

Cited by 9 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reports have also shown pancreatic, gastric, duodenal, appendiceal, and rectal neuroendocrine tumors with positive staining for PAX-8 [20][21][22] as well as Ewing sarcomas. 23 PAX-8 expression has been described in breast carcinoma and is an interesting finding. One study demonstrated variable weak to strong PAX-8 staining in breast carcinomas (including mucinous, micropapillary, lobular, and ductal subtypes).…”

Section: Discussionmentioning

confidence: 86%

PAX-8 Expression in Salivary Duct Carcinoma

Serinelli

Mirchia²,

Gitto³

et al. 2021

Applied Immunohistochemistry &Amp; Molecular Morphology

View full text Add to dashboard Cite

Salivary duct carcinoma (SDC) is a high-grade adenocarcinoma resembling breast ductal carcinoma. It accounts for ~10% of malignant tumors of the salivary glands. Most cases show expression of CK7 and androgen receptor. PAX-8 is a transcription factor, with expression reported in renal, Müllerian, and thyroid carcinomas. Previous studies have described an absence of PAX-8 immunostaining in most primary salivary gland neoplasms, including SDCs. However, PAX-8 expression is frequently found in neoplasms that can metastasize to salivary glands, suggesting the possibility that this protein can be used to differentiate SDC from secondary neoplastic involvement of the salivary gland. We evaluated the expression of PAX-8 in 14 cases of SDC from our institution. One case showed diffuse moderate to strong PAX-8 positivity, while 2 tumors showed focal weak staining. Therefore, we conclude that although the majority of SDC are negative for PAX-8, rare diffuse positivity can be seen in these primary salivary gland tumors. This could potentially pose difficulty in ruling out metastatic disease from another PAX-8-positive primary neoplasm.

show abstract

Section: Discussionmentioning

confidence: 86%

PAX-8 Expression in Salivary Duct Carcinoma

Serinelli

Mirchia²,

Gitto³

et al. 2021

Applied Immunohistochemistry &Amp; Molecular Morphology

View full text Add to dashboard Cite

show abstract

“…CD99 positivity is seen in approximately 95% of ES/PNETs. 16 NKX2.2 positivity is more specific than CD99. 17 Keratin expression is seen in 25% of cases.…”

Section: Discussionmentioning

confidence: 92%

Ewing Sarcoma/Primitive Neuroectodermal Tumor Involving the Duodenum

Tafti

Yoon

Fitzgerald

et al. 2022

TOJ

View full text Add to dashboard Cite

Background: Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) is a soft tissue malignancy arising from the neuroectoderm. While the locations of these extraskeletal manifestations are diverse, origin from the small bowel and small bowel mesentery is extremely rare. Intra-abdominal manifestations of ES/PNETs are nonspecific, and patients present with a wide range of symptoms, most frequently vague abdominal pain. Case Report: A 66-year-old female initially presented with vague and nonspecific symptoms of hypotension, anemia, dyspnea, and coffee-ground emesis. Imaging workup with computed tomography and fluorodeoxyglucose positron emission tomography demonstrated a metabolically active large mass involving the duodenum and measuring 10.3 × 8.8 × 12.3 cm. The mass was characterized as an ES/PNET on histopathologic diagnosis. The patient was treated with chemotherapy followed by radical resection and was disease-free at 1 year postpresentation. Conclusion: This case highlights that while ES/PNETs are rare tumors of the abdomen, they should be considered in cases of large soft tissue masses in patients presenting with nonspecific symptoms. To the best of our knowledge, this case is the fourth report in the literature of an ES/PNET involving the duodenum.

show abstract

“… 21 , 22 However, despite high sensitivity, it is a nonspecific marker owing to its expression in other tumors like anaplastic large‐cell lymphoma, lymphoblastic lymphoma, synovial sarcoma (round‐cell variant), etc. 23 Similarly, vimentin is a constituent of intermediate filament, expressed in normal mesenchymal cells and provides resistance against stress. 24 The ES stains strongly for vimentin compared to lymphoblastic lymphoma.…”

Section: Discussionmentioning

confidence: 99%

A case report on non‐metastatic Ewing sarcoma of the lumbar spine in a young patient

et al. 2022

View full text Add to dashboard Cite

Background: Ewing sarcoma (ES), the second most common malignant bone tumor after osteosarcoma in the second decade, occurs in 0.9% of cases as the primary non-sacral form.Case: A 20-years-old male presented with acute paraparesis of bilateral lower limb and numbness following initial back pain for the last 6 months. Magnetic resonance imaging (MRI) of the lumbar spine revealed a 4 cm enhancing soft tissue mass at the L4/L5 vertebra extending into the spinal canal with compression of the thecal sac.The computed tomography (CT) of the chest, abdomen, and pelvis revealed aggressive lytic lesions in the L4 spinous process with soft tissue extension into the spinal canal with no other site of distant metastasis. He was treated with IV steroids (Injection dexamethasone 10 mg IV followed by 4 mg tablet dexamethasone q6h; subsequently tapered off). A core needle biopsy showed a small, round blue cell neoplasm, (suggestive of a primitive neuroectodermal) stained positive for CD99 and vimentin stain. The diagnosis of ES lumbar spine was made which was treated with surgical resection with an appropriate margin measuring 8 Â 4.5 Â 2.5 cm with decompression and L4/5 laminectomies, which had a negative margin in the surgical pathology report. Concomitant local radiotherapy and chemotherapy [cycles of vincristine 2 mg/m 2 , adriamycin/doxorubicin 75 mg/m 2 , cyclophosphamide 1200 mg/m 2 (VDC) with mesna rescue alternating with cycles of ifosfamide 1800 mg/m 2 and etoposide 100 mg/m 2 (IE)] was started. The motor strength was regained gradually with preserved spine biomechanics and oncological control with no recurrence in 2-year follow-ups. Conclusions:The presentation of lumbar ES can vary from local pain and swelling to acute paraparesis. Timely diagnosis and treatment with multimodal therapy, namely, steroids for acute spinal cord compression and surgery with chemoradiotherapy for ES can improve spinal biomechanics and oncological control.

show abstract

Immunohistochemical Analysis of CD99 and PAX8 in a Series of 15 Molecularly Confirmed Cases of Ewing Sarcoma

Cited by 9 publications

References 30 publications

PAX-8 Expression in Salivary Duct Carcinoma

PAX-8 Expression in Salivary Duct Carcinoma

Ewing Sarcoma/Primitive Neuroectodermal Tumor Involving the Duodenum

A case report on non‐metastatic Ewing sarcoma of the lumbar spine in a young patient

Contact Info

Product

Resources

About